Table 2.
Comparison of patient-reported outcomes between the concordant and discordant groups in the prospective substudy
| Patient-reported outcome | Concordant group (n = 20) |
Discordant groupa
(n = 46) |
P value |
|---|---|---|---|
| Pain VAS | 25.0 (11.0–42.5) | 49.0 (28.0–70.0) | .002 |
| SF-MPQ-2 pain score | |||
| Continuous | 2.2 (1.8) | 3.3 (2.0) | .03 |
| Intermittent | 1.8 (2.2) | 1.8 (2.0) | .71 |
| Neuropathic | 1.2 (1.4) | 2.0 (1.8) | .045 |
| Affective | 1.1 (1.4) | 1.7 (2.0) | .06 |
| Total | 1.2 (0.4–2.7) | 2.1 (1.2–2.9) | .09 |
| Fibromyalgia Research Survey | |||
| WPI | 4.5 (2.5–7.0) | 7.0 (5.0–10.0) | .008 |
| SS score | 3.5 (2.0–5.5) | 4.5 (3.0–6.0) | .05 |
| Polysymptomatic distress | 7.5 (5.5–12.5) | 11.5 (9.0–16.0) | .007 |
| BRAF score | 5.0 (3.8–5.5) | 5.3 (4.3–6.7) | .10 |
| PROMIS | |||
| Fatigue | 2.4 (1.4–3.4) | 2.8 (2.0–3.8) | .22 |
| Pain interference | 1.7 (1.3–2.6) | 2.2 (1.6–3.1) | .04 |
| Sleep disturbance | 2.0 (1.4–3.4) | 2.8 (2.0–3.8) | .09 |
| Ability to participate | 3.9 (3.4–4.5) | 3.5 (3.0–4.1) | .06 |
| HAQ-II disability | 0.4 (0.1–1.1) | 1.0 (0.5–1.4) | .003 |
| MAAS | 4.6 (4.2–5.3) | 5.1 (4.5–5.4) | .19 |
| PHQ-9 | 2.5 (1.0–6.0) | 4.0 (3.0–6.0) | .18 |
| GAD-7 | 1.0 (0.0–1.5) | 1.0 (0.0–3.0) | .12 |
Values are presented as median (interquartile range)
a Discordant group contains only those patients with patient global assessment greater than physician global assessmen
BRAF Bristol Rheumatoid Arthritis Fatigue, GAD-7 Generalized Anxiety Disorder 7, HAQ-II Health Assessment Questionnaire II, MAAS Mindful Attention Awareness Scale, PHQ-9 Patient Health Questionnaire 9, PROMIS Patient-Reported Outcome Measurement Information System, SF-MPQ-2 Short-Form McGill Pain Questionnaire 2, SS Symptom Severity, VAS visual analog scale, WPI Widespread Pain Index